Shattuck Labs saw the highest growth of 6.99% in patent filings in May and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.49% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Shattuck Labs’s patent filings and grants. Buy the databook here.
Shattuck Labs has been focused on protecting inventions in United States(US) with four publications in Q2 2024
The United States(US) Patent Office dominates the patent filings with nearly 36% of filings. The United States(US), World Intellectual Property Organization(WIPO), Australia(AU), and Israel(IL) patent Office are among the top ten patent offices where Shattuck Labs is filings its patents. Among the top granted patent authorities, Shattuck Labs has 100% of its grants in Israel(IL).
Regeneron Pharmaceuticals and Roche could be the strongest competitors for Shattuck Labs
Patents related to nanomedicine lead Shattuck Labs's portfolio
Shattuck Labs has the highest number of patents in nanomedicine. For nanomedicine, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Inflammation related patents lead Shattuck Labs portfolio followed by metabolic syndrome, and obesity
Shattuck Labs has highest number of patents in inflammation followed by metabolic syndrome, obesity, non alcoholic fatty liver disease (nafld), and steatohepatitis.
For comprehensive analysis of Shattuck Labs's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.